The estimated Net Worth of Jeffrey Chodakewitz is at least $20.9 Milione dollars as of 12 February 2018. Jeffrey Chodakewitz owns over 5,122 units of resTORbio stock worth over $1,713,361 and over the last 10 years he sold TORC stock worth over $19,185,235. In addition, he makes $0 as Independent Director at resTORbio.
Jeffrey has made over 34 trades of the resTORbio stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 5,122 units of TORC stock worth $772,500 on 12 February 2018.
The largest trade he's ever made was selling 60,000 units of resTORbio stock on 31 October 2017 worth over $8,703,000. On average, Jeffrey trades about 4,222 units every 20 days since 2014. As of 12 February 2018 he still owns at least 69,663 units of resTORbio stock.
You can see the complete history of Jeffrey Chodakewitz stock trades at the bottom of the page.
Dr. Jeffrey A. Chodakewitz M.D. serves as Independent Director of the Company. From April 2018 through March 2019, Dr. Chodakewitz served as Executive Vice President, Clinical Medicine and External Innovation, at Vertex Pharmaceuticals. Prior to that role, Dr. Chodakewitz held the roles of Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs at Vertex from January 2014 to April 2018 and was a member of the Vertex Executive Committee. Prior to joining Vertex in January 2014, he spent over 20 years at Merck & Co., where he served in a number of positions including Head of Infectious Diseases and Vaccines Global Development from August 2013 to December 2013, Senior Vice President of Global Scientific Strategy (Infectious Disease, Respiratory & Immunology) from January 2013 to August 2013 and Senior Vice President of Late Stage Development from March 2011 to January 2013. Dr. Chodakewitz is a Diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine (both Internal Medicine and Infectious Disease). Dr. Chodakewitz currently serves on the board of Tetraphase Pharmaceuticals, Inc. He holds a B.S in Biochemistry cum laude from Yale University and an M.D. from the Yale University School of Medicine. Chodakewitz is qualified to serve on our board of directors as a result of his extensive experience working for various pharmaceutical and biotechnology companies.
Jeffrey Chodakewitz is 64, he's been the Independent Director of resTORbio since 2018. There are no older and 6 younger executives at resTORbio.
Jeffrey's mailing address filed with the SEC is C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 10036.
Over the last 7 years, insiders at resTORbio have traded over $9,290,741 worth of resTORbio stock and bought 1,305,999 units worth $19,553,525 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Health Llc Pure Tech e Jonathan Silverstein. On average, resTORbio executives and independent directors trade stock every 69 days with the average trade being worth of $22,102,789. The most recent stock trade was executed by Health Llc Pure Tech on 18 December 2019, trading 6,161,531 units of TORC stock currently worth $7,393,837.
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
resTORbio executives and other stock owners filed with the SEC include: